"Bromhexine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
| Descriptor ID |
D001964
|
| MeSH Number(s) |
D02.092.146.271 D02.092.384.175
|
| Concept/Terms |
Bromhexin BC- Bromhexin BC
- BC, Bromhexin
- Bromhexin Berlin-Chemie
- Bromhexin Berlin Chemie
- Bromhexin BerlinChemie
Bromhexine Hydrochloride- Bromhexine Hydrochloride
- Hydrochloride, Bromhexine
- Bromhexine Monohydrochloride
- Monohydrochloride, Bromhexine
Brotussol- Brotussol
- bromhexin von ct
- ct, bromhexin von
- von ct, bromhexin
Hustentabs-ratiopharm- Hustentabs-ratiopharm
- Hustentabs ratiopharm
- Hustentabsratiopharm
- Bromhexin-ratiopharm
- Bromhexin ratiopharm
- Bromhexinratiopharm
|
Below are MeSH descriptors whose meaning is more general than "Bromhexine".
Below are MeSH descriptors whose meaning is more specific than "Bromhexine".
This graph shows the total number of publications written about "Bromhexine" by people in this website by year, and whether "Bromhexine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Bromhexine" by people in Profiles.
-
New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial). BMJ Open. 2021 08 03; 11(8):e045190.
-
SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. J Virol. 2021 04 12; 95(9).
-
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS One. 2021; 16(3):e0248132.
-
[Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for Coron?virUs Infection requiring hospiTalization (BISCUIT)]. Kardiologiia. 2020 12 03; 60(11):4-15.
-
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study. Clin Transl Sci. 2020 11; 13(6):1096-1102.
-
Evaluating the efficacy and safety of bromhexine hydrochloride tablets in treating pediatric COVID-19: A protocol for meta-analysis and systematic review. Medicine (Baltimore). 2020 Sep 11; 99(37):e22114.
-
[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for Coron?virUs Infection requiring hospiTalization (BISCUIT)"]. Kardiologiia. 2020 Sep 07; 60(8):4-15.
-
Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19. Eur J Clin Pharmacol. 2021 Feb; 77(2):261-263.
-
Pulmonary surfactant itself must be a strong defender against SARS-CoV-2. Med Hypotheses. 2020 Nov; 144:110020.
-
Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? Intern Emerg Med. 2020 Aug; 15(5):801-812.